Burke, Teresa F.
Eli Lilly (United States)
2 papers on CoChat
Most cited papers
- Verified
The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation
Yadav, V., Burke, T. F., Huber, L., Van Horn, R. D., Zhang, Y., Buchanan, S. G., Chan, E. M., Starling, J. J., Beckmann, R. P., & Peng, S.-B. (2014) · Molecular Cancer Therapeutics
Melanoma and MAPK PathwaysAdvanced Breast Cancer Therapies
Cited by 132
- Verified
Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts
Tate, S. C., Cai, S., Ajamie, R. T., Burke, T., Beckmann, R. P., Chan, E. M., De Dios, A., Wishart, G. N., Gelbert, L. M., & Cronier, D. M. (2014) · Clinical Cancer Research
Advanced Breast Cancer TherapiesMathematical Biology Tumor Growth
Cited by 130
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free